These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
167 related articles for article (PubMed ID: 8011734)
41. Immunostimulatory monoclonal antibodies for cancer therapy. Melero I; Hervas-Stubbs S; Glennie M; Pardoll DM; Chen L Nat Rev Cancer; 2007 Feb; 7(2):95-106. PubMed ID: 17251916 [TBL] [Abstract][Full Text] [Related]
42. A human tumor xenograft model of therapy with a bispecific monoclonal antibody targeting c-erbB-2 and CD16. Weiner LM; Holmes M; Adams GP; LaCreta F; Watts P; Garcia de Palazzo I Cancer Res; 1993 Jan; 53(1):94-100. PubMed ID: 8093231 [TBL] [Abstract][Full Text] [Related]
44. Introduction: methodology for detection of antigens in preneoplastic and neoplastic tissues. Borsos T Natl Cancer Inst Monogr; 1972 Dec; 35():3-4. PubMed ID: 4659053 [No Abstract] [Full Text] [Related]
45. Cancer vaccines. Dalgleish AG Br J Cancer; 2000 May; 82(10):1619-24. PubMed ID: 10817493 [No Abstract] [Full Text] [Related]
46. Cellular immunity to tumor-associated antigens in man. Hellström KE; Hellström I N Engl J Med; 1977 Apr; 296(15):874-5. PubMed ID: 321957 [No Abstract] [Full Text] [Related]
47. Principles and use of anti-CTLA4 antibody in human cancer immunotherapy. Peggs KS; Quezada SA; Korman AJ; Allison JP Curr Opin Immunol; 2006 Apr; 18(2):206-13. PubMed ID: 16464564 [TBL] [Abstract][Full Text] [Related]
48. Paraneoplastic neurologic disorders: windows into neuronal function and tumor immunity. Darnell RB Arch Neurol; 2004 Jan; 61(1):30-2. PubMed ID: 14732616 [No Abstract] [Full Text] [Related]
50. [Development of anti-cancer drugs based on molecular targeting and their application to brain tumor therapy]. Shiraishi T; Tabuchi K No Shinkei Geka; 2003 Apr; 31(4):365-81. PubMed ID: 12704818 [No Abstract] [Full Text] [Related]
51. Targeting cancer stem cells with monoclonal antibodies: a new perspective in cancer therapy and diagnosis. Okamoto OK; Perez JF Expert Rev Mol Diagn; 2008 Jul; 8(4):387-93. PubMed ID: 18598221 [TBL] [Abstract][Full Text] [Related]
52. [Introduction to the International Symposium on Tumor Immunotherapy]. De Barbieri A Boll Ist Sieroter Milan; 1971; 50(3):137-9. PubMed ID: 5146576 [No Abstract] [Full Text] [Related]
53. Tumor immunology. Shehadeh IH J Med Liban; 1972; 25(3):199-203. PubMed ID: 5086706 [No Abstract] [Full Text] [Related]
54. Dendritic cell vaccines for cancer therapy. Sprinzl GM; Kacani L; Schrott-Fischer A; Romani N; Thumfart WF Cancer Treat Rev; 2001 Aug; 27(4):247-55. PubMed ID: 11545544 [TBL] [Abstract][Full Text] [Related]
55. [Tumor immunological evasiveness]. Turtureanu-Hanganu E Rev Med Chir Soc Med Nat Iasi; 1989; 93(4):758. PubMed ID: 2636777 [No Abstract] [Full Text] [Related]
56. Monoclonal antibodies in cancer therapy. Scott AM; Allison JP; Wolchok JD Cancer Immun; 2012; 12():14. PubMed ID: 22896759 [No Abstract] [Full Text] [Related]
57. The regulation of the human antitumor immune response to organ-specific neoantigens. Thomson DM; Phelan K; Scanzano R; Fink A Transplant Proc; 1981 Dec; 13(4):1952-4. PubMed ID: 6277060 [No Abstract] [Full Text] [Related]
58. [Immunological phenomenons and cancer]. Burtin P Ann Inst Pasteur (Paris); 1972 Apr; 122(4):589-92. PubMed ID: 5050869 [No Abstract] [Full Text] [Related]
59. Monoclonal antibodies for imaging and therapy. Epenetos AA; Kosmas C Br J Cancer; 1989 Feb; 59(2):152-5. PubMed ID: 2649128 [No Abstract] [Full Text] [Related]